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Introduction
In July of 2009 the U.S. Food and Drug Administra-
tion enacted new regulation of colchicine under the
“Unapproved Drugs Program.” Like other old drugs that
were on the market before the existence of the FDA, col-
chicine had never been subjected to FDA-required safety
and efficacy trials. One company elected to put colchicine
through the FDA’s approval protocol and when approval
was granted in 2009 the FDA announced a ban on five
unapproved brands of colchicine on the market and gave
proprietary rights to one approved brand. The sudden
brand changes that followed this regulation led to a thera-
peutic crisis for FMF patients in the U.S. and coinciden-
tally revealed heretofore unrecognized patterns in patient
response to different brands of colchicine.
Objectives
To document and characterize the brand specific response
of individual FMF patients participating in FMF support
groups on the internet and determine the potential of
multiple brand exposure for improving the effectiveness of
colchicine by reducing intolerance and resistance rates.
Methods
An online survey of FMF patients participating in patient
support groups on Facebook and Yahoo was conducted.
Patients residing in the U.S. were selected and were asked
to report each brand of colchicine they had ever taken and
to indicate for each brand whether their response was
satisfactory; unsatisfactory, but kept taking it; or unsatis-
factory and discontinued it.
Results
40 FMF patients reported taking 11 brands of colchicine;
a total of 101 individual/brand trials. Of 31 patients taking
2 or more brands, 3 brands was the average number tried.
FMF patients revealed a highly idiosyncratic response
to different brands of colchicine. Adverse responses and
ineffectiveness were common for all brands ranging from
81% (FDA approved brand) to 30% (FDA banned brand).
A critical finding was that all 9 patients discontinuing
a brand for ineffectiveness (“colchicine resistance”) had
a satisfactory response to another brand. Despite the
frequency of adverse responses (intolerance or ineffective-
ness) to individual brands, all patients with exposure to
2 or more brands reported a satisfactory response to at
least one brand.
Conclusion
Intolerance and ineffectiveness (i.e. “colchicine resistance”)
are not characteristics of FMF patients but are idiosyn-
cratic brand responses. Most FMF patients could achieve a
satisfactory therapeutic response to colchicine if a mini-
mum of three independent brands were available to them.
Wider availability of colchicine brand options are needed
for all FMF patients. Before resorting to alternative higher-
risk drugs, FMF patients should be shown to be intolerant
to 3 independent brands of colchicine. Although this is a
clinically simple therapeutic strategy, the greater challenge
is the maze of regulations governing the importation of
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